Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nektar Quiets Partnering Talk, Will Keep Oncology Drug For Itself

This article was originally published in The Pink Sheet Daily

Executive Summary

Auspicious data from a pair of Phase II studies has prompted the company to cease partnership discussions - and reassess its priorities.

You may also be interested in...



Nektar Readies Phase III Breast Cancer Trial Of NKTR-102, On Its Own

Nektar Therapeutics Inc. will launch the Phase III BEACON trial by the end of this year for its NKTR-102, a next-generation version of the now generic topoisomerase 1 inhibitor irinotecan (Pfizer Inc.’s Camptosar). The trial, in pretreated metastatic breast cancer patients, will have a raft of endpoints designed to help gain acceptance in the crowded field.

Nektar Readies Phase III Breast Cancer Trial Of NKTR-102, On Its Own

Nektar Therapeutics Inc. will launch the Phase III BEACON trial by the end of this year for its NKTR-102, a next-generation version of the now generic topoisomerase 1 inhibitor irinotecan (Pfizer Inc.’s Camptosar). The trial, in pretreated metastatic breast cancer patients, will have a raft of endpoints designed to help gain acceptance in the crowded field.

Nektar/Bayer Agree To Develop Inhaled Amikacin For Hospital-Acquired Pneumonia

Product combining Nektar’s deep-lung delivery technology and amikacin formulation could reach market in 2010-2011 timeframe, Nektar COO tells “The Pink Sheet” DAILY.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071602

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel